- * -

Keliang Gao, Ph.D.

Address: **** ********* **, ***** *********, OH 43220

Ema i l : acrz1a@r.postjobfree.com

Mobile: 740-***-****

STRENGTHS

Broad knowledge and extensive research experiences in chemical engineering and bioengineering, including cell biology, fermentation, protein production and purification, biological/chemical drug synthesis, biocatalysis and biotransformation, nanotechnology, biochip/medical device design and fabrication.

Experienced in multi-phase project management.

Demonstrated problem solving ability in research and industrial settings.

Knowledge and hands-on experiences in bioreactor (up to 300 liters in lab), HPLC, GC, SEM, PCR (real-time PCR, RT-PCR, and single cell qRT-PCR), nanoelectroporation for drug delivery and gene transfection, optical tweezers, surface modification, high pressure hydrogenation, photo lithography, and cleanroom technologies. KEY RESEARCH ACCOMPLISHMENTS

1. Nanotechnology for DNA/RNA/drug delivery into cancer cells for chemo-therapy. Collected and analyzed users requirements, and developed nanochannel array based biochip

(100nm wide nanochannel, 300 nanochannels array) for precise dosage DNA/RNA/drug delivery and biological/medical research. The chip is used for siRNA induced apoptosis in leukemia cancer to investigate the machennism.

2. Chemical engineering/nanotechnology for early cancer detection using extracellular vesicles. Summarized and analyzed users requirements, and developed nanoparticle based biochip for early detection of lung cancer, liver cancer, sepsis, and so on. The novel nanotechnology focused on exosome in serum or body fluid.

3. Nanotechnology for induced pluripotent stem cells for gene therapy. Collected and analyzed users experiences, and applied biochips of nanochannel electroporation for induction of iPSC for clinical application. It was also used for induced neurone.

4. Novel Pharmaceutical for Diabetes

Led a group in developing a novel drug for treating diabetes, prepared essential documents to satisfy commercial operation and government regulatory requirements. The drug has been approved by China Food and Drug Administration. The developed technology is estimated at a total value of $2,500,000, and has been transferred to a pharmaceutical company for $1,500,000 plus royalty agreements.

- 2 -

5. High Density Fermentation for drug and protein production Increased microbial cell density by 300% after optimizing for high density fermentation. Scaled up the technology from lab to industrial operation (from 5ml to 600L, for fed-batch, semi-continuous, and continuous fermentation) and developed supporting techniques. 6. Resting Cell Technique

Obtained high endoenzyme activity consistently for 5 batches of biotransformation of pharmaceutical precursor (β-glucosidase inhibitor), with the transformation yields increased from 60% to 90%. The high yield reduced the possibility of isomer formation to less than 1% and decreased cost of separation by 80%.

7. Biocatalysis of Antibiotics (Cefaclor)

Developed a new method which increased the yield of production by 45%, and minimized the environmental pollution.

8. Fermentation of Fungi and Enzyme for Biosynthesis in Organic Solvent High density fermentation of fungi reached 400g/L with high enzymatic activity in organic solvent. This technique has been transferred to an industrial company. 9. Microtechnology and biochip

Micro-scale ELISA was developed with 90% lower cost than conventional ELISA. 10. Feedback Control Biosynthesis

Increased the production yield from 60% to 95% while decreased cost of separation by 80%. PROFESSIONAL EXPERIENCE

2010---2014 Visiting Scholar

NSF Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymer Biomedical Devices, The Ohio State University, Columbus, OH 2000---2010 Assistant Professor, Research Associate State Key Laboratory of Bioreactor Engineering, China East China University of Science and Technology, Shanghai, P.R. China Institute of Biotechnology, Lunan Pharmaceutical Group Corp. (Top 100 pharmaceutical companies in China)

1997---2000 Research Assistant

Key Laboratory of Industrial Biotechnology, Ministry of Education, China Jiangnan University, P.R. China. Yanghe Group Corp. (Top 3 distilleries in China) JOURNAL REVIEWER:

Biotechnol & Bioeng., Appl. Microbiology and Biotechnology, Process Biotechnology

- 3 -

ATTACHMENT

I. Major Publications

1. Keliang Gao, et al. submitted to Nature Biotechnology 2. Keliang Gao, et al. Small, 2014, 10(5): 1015–1023 3. Pouyan E. Boukany, et al. Nature Nanotechnology, 2011, 6: 747-754. 4. Keliang Gao, et al. J. Chemical Technology & Biotechnology, 2009, 84(11): 1742–1746. 5. Keliang Gao, et al. Journal of Biotechnology, 2008, 136S: S398. 6. Keliang Gao, et al. Applied Microbiology and Biotechnology, 2006, 71(6): 819-823. 7. Keliang Gao, et al. Applied Microbiology and Biotechnology, 2006, 70(2): 135-139. II. Award

1. Excellent Young Teacher of Universities, awarded by Shanghai Municipal Government, 2009, 50,000 III. Technology transfer

1. Miglitol (pharmaceutical for diabetes), approved by SFDA and commercialized by Lunan Pharmaceutical Group Corp. IV. Other Publications

1. Liujing Wei, et al. Mol Biotechnol (2010) 46:26–33. 2. Shuwei Yan, et al. J. East China Univ. Sci & Technol, 2009, 4: 549-553. 3. Erzheng Su, et al. J. Molecular Catalysis B: Enzymatic, 2007,48: 28-32. 4. Keliang Gao, et al. J East China Univ. Sci & Technol, 2007, 33(6):798-802. 5. Wu Su, et al. Tetrahedron: Asymmetry, 2004, 15(8): 1275-1277. 6. Yan Xu, et al. Industrial Microbiology, 2000,30(3):8-11. V. Patents and other ACHIEVEMENS

1. Keliang Gao, et al. AICHE, 2013

2. Xi Zhao, et al. AICHE, 2011

3. Kwang Joo Kwak, et al. AICHE, 2010

4. Keliang Gao, et al. The 3rd National Chemical and Biochemical Engineering Annual Meeting, 2006.11, 982. 5. Keliang Gao, et al. International Symposium on Biocatalysis and Bioprocess Engineering, 2005, China. 6. Keliang Gao, et al. Chinese materials Forum 2004 (D. Branch of biomedical materials), 2004, 22-26. 7. Wu Su, et al. CN 1563396A, Application: CN 2004-10016935.5, 2004. 8. Keliang Gao, et al. International Symposium on Bioprocess and Biomolecular Engineering, 2003, China. 9. Authorization on clinical research of miglitol tablet, State food and drug administration of China, No. 2004L02033. 10. Study on scale up of preparation of coco-butter equivalent by microbial catalysis esterafication, authenticated by Science and Technology Commission of Shanghai Municipality, China, No. 0069238.

Contact this candidate